Advertisement


Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

2015 ASH Annual Meeting

Advertisement

Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).



Related Videos

Lymphoma

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Leukemia

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).

Symptom Management

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Advertisement

Advertisement




Advertisement